ACTG A5320

Participant Summary Sheet


Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)


Brief Description

This study is for men and women who are HIV+ AND have Hepatitis C infection (co-infection) and for men and women who have Hepatitis C infection ALONE (mono-infection). Participants can begin a new Hep C treatment as part of a clinical trial after (V-HICS) study enrollment. The study will collect blood in order to look at and compare the differences in each person’s Hepatitis C virus and genetic differences between each person that might play a role in the success or failure of the Hep C treatments. This study will use a questionnaire to measure each person’s quality of life and how treatment success or failure affects quality of life.  Each person will have already received and completed treatment for Hepatitis C as part of a clinical trial or study in the past 12 months. People can NOT be on Hepatitis C treatment at the time of (V-HICS) study enrollment.      

Purpose of

The Study 

This study will help to understand the impact of successful (sustained viral response) or unsuccessful Hepatitis C virus treatment on a persons health over many years. It will also help us understand how long resistance to new HCV medications lasts in a person and whether it affects future HCV treatments.


to Enter Study

HIV+/Hep C co-infected men and women who are at least 18 years of age


HCV mono-infected men and women who are at least 18 years of age

Completed treatment for Hep C in the last 12 months as part of a clinical trial

Not currently on Hep C treatment

Willingness to adhere to study visits twice a year AND a one time visit prior to starting any new Hep C treatment study after (V-HICS) study enrollment


None (this an observational study and does not provide any medication)

Duration of Study

Each participant will be followed for 5 years.

For more information contact:

Ericka R. Patrick, RN, MSN